Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MTOR | P42345 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.43 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.43 |
| ▸ | GMNN | O75496 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | HBB | P68871 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8847369 | 0.91 | ADORA1 (0.49) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL25407280 | 0.86 | LMNA (0.47) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL21999226 | 0.86 | LMNA (0.47) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL21999057 | 0.86 | LMNA (0.47) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL23547707 | 0.86 | LMNA (0.47) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL17803622 | 0.86 | LMNA (0.56) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL31348019 | 0.85 | RNASEL (0.49) | RNASELADORA1P2RY1P2RY11 | |
| SCHEMBL15329176 | 0.85 | ADORA1 (0.35) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL15329181 | 0.84 | LMNA (0.33) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL11802932 | 0.83 | LMNA (0.47) | LMNAMTORTHRBMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025068557-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | CONTERA PHARMA A/S (DK) | 2025-04-03 | — | — | WO | claimed |
| US-20260103714-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | CONTERA PHARMA AS (DK) | 2026-04-16 | — | — | US | disclosed |
| EP-4720283-A1 | OLIGONUCLEOTIDES TARGETING GAL3ST1 | Contera Pharma A/S (DK) | 2026-04-08 | — | — | EP | disclosed |
| US-20260035702-A1 | PLASMINOGEN (PLG) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260015617-A1 | DOUBLE STRANDED RNAi AGENTS, COMPOSITIONS AND METHODS OF USE | NOVARTIS AG (CH) | 2026-01-15 | — | — | US | disclosed |
| US-20250333737-A1 | 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | REGENERON PHARMA (US) | 2025-10-30 | — | — | US | disclosed |
| US-12416006-B2 | Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250270562-A1 | BIS-RNAI COMPOUNDS FOR CNS DELIVERY | BANK OF AMERICA, N.A. | 2025-08-28 | — | — | US | disclosed |
| US-20250257351-A1 | REVERSIR TM COMPOUNDS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-08-14 | — | — | US | disclosed |
| EP-4594491-A2 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | Contera Pharma A/S (DK) | 2025-08-06 | — | — | EP | disclosed |
| US-20240011032-A1 | SNCA IRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING SNCA-ASSOCIATED NEURODEGENERATIVE DISEASES | BANK OF AMERICA, N.A. | 2024-01-11 | — | — | US | disclosed |
| US-20230332147-A1 | IRNA COMPOSITIONS AND METHODS FOR SILENCING GROWTH FACTOR RECEPTOR BOUND PROTEIN 10 (GRB10) OR GROWTH FACTOR RECEPTOR BOUND PROTEIN 14 (GRB14) IN THE LIVER | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230323357-A1 | TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6 (TRAF6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| EP-3794122-B1 | ANGIOTENSINOGEN (AGT) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS INC (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20230193268-A1 | APOLIPOPROTEIN E (APOE) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2023-06-22 | — | — | US | disclosed |
| US-20230032974-A1 | SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2023-02-02 | — | — | US | disclosed |
| US-11446380-B2 | Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220259589-A9 | REVERSIR TM COMPOUNDS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-08-18 | — | — | US | disclosed |
| EP-4039809-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION | Alnylam Pharmaceuticals, Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| US-20220127604-A1 | REVERSIR TM COMPOUNDS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015617-A1 | DOUBLE STRANDED RNAi AGENTS, COMPOSITIONS AND METHODS OF USE | HMGCR, APOL1, LDLR | LMNA 58/4885MTOR 4579/4885THRB 3968/4885 |
| US-12416006-B2 | Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereof | EIF2AK2, DCLRE1B, DNASE1L3 | LMNA 242/4885MTOR 3712/4885THRB 3338/4885 |
| US-11446380-B2 | Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression | HAO1, HAO2, HAAO | LMNA 4179/4885MTOR 4617/4885THRB 4007/4885 |
| US-20230323357-A1 | TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6 (TRAF6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | TRAF6, TRAF2, TNFRSF1A | LMNA 1339/4885MTOR 2771/4885THRB 2633/4885 |
| US-20240011032-A1 | SNCA IRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING SNCA-ASSOCIATED NEURODEGENERATIVE DISEASES | SNCA, SYNCRIP, PARK7 | LMNA 293/4885MTOR 2898/4885THRB 3730/4885 |
| US-20230032974-A1 | SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | RPS25, RBM25, RPS26 | LMNA 1276/4885MTOR 611/4885THRB 4224/4885 |
| US-20260103714-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | NAT10, NAT1, NAA40 | LMNA 310/4885MTOR 4237/4885THRB 1066/4885 |
| US-20260035702-A1 | PLASMINOGEN (PLG) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | PLG, PLAU, PLAUR | LMNA 20/4885MTOR 4722/4885THRB 2078/4885 |
| US-20230193268-A1 | APOLIPOPROTEIN E (APOE) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | APOL1, APOB, SNRPE | LMNA 212/4885MTOR 4713/4885THRB 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.